Affimed N.V.

Good day, everyone, and welcome to AffiMed's second quarter 2024 earnings and corporate update call. At this time, all participants are on a listen-only mode. To ask a question during the Q&A session, you will need to press star 1-1 on your telephone. You will then hear an automatic message advising your hand is raised. As a reminder, today's conference call is being recorded. I would now like to introduce your host for today's call, Alex Medicatus, Head of Industrial Relations at AffiMed. Please go ahead.

Thank you, Livia. And thank you all for joining us today for our second quarter 2024 update call. Before we begin, I'd like to remind everyone that we issued the relevant press release earlier today, and that can be found on our investor relations section of the website. On our website, you can also find the presentation we will be using today. On the call today, we have members of our management team, including Sean Leland, our new chief executive officer, Andreas Harstrig, our Chief Medical Officer, Wolfgang Fischer, our Chief Operating Officer, Denise Mueller, our Chief Business Officer, and Harry Welton, our Consulting Chief Financial Officer. Our financials today will be presented by our VP of Finance, Michael Wolf. The team will be available for Q&A after the prepared remarks. Before we start, I would like to remind you that today's presentation contains projections and forward-looking statements regarding future events. These statements represent our beliefs and assumptions only as of the date of this call. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. These forward-looking statements are subject to risks and uncertainties, And actual results may differ materially from those expressed or implied in these statements due to various factors, including but not limited to those identified under the section entitled risk factors in our filings with the SEC and those identified under the section entitled forward-looking statements in the press release that we issued today and filed with the SEC. With that, I'll turn the call over to Sean. Sean?

Thank you, Alex, and good morning, everyone. I'm excited to speak with you today as the new CEO of AFIMED. Although I am only a few days into this role, I'm eager to share my initial thoughts with our shareholders and the financial community. My decision to join AFIMED was data-driven. After thoroughly reviewing AFIMED's portfolio of innate cell engagers, I'm impressed with the platform and firmly believe we are on the verge of something transformational. The commercial potential is quite significant as we have achieved clinical proof of concept across three assets, each with distinct indications. This progress is particularly encouraging for the many advanced refractory or relapse patients who have limited options across indications such as non-small cell lung cancer, Hodgkin lymphoma, and acute myeloid leukemia. Importantly, Affymed's diverse clinical portfolio offers valuable strategic options for our business and, from my perspective, is an enviable position in the biotech world. My immediate commitment to you, our shareholders, is to hit the ground running and to secure funding to support our promising clinical programs. I look forward to engaging with our current shareholders and prospective investors alike I will be speaking with those already familiar with the current AFIMED data and new investors to share my enthusiasm over the clinical pipeline poised for numerous data readouts in the next 12 to 24 months. Although the capital markets have been challenging to biotechs in 2024, I am confident our compelling clinical data differentiates us and will allow us to further extend our runway. Additionally, I am energized to thoroughly examine our business development strategy and broaden our relationships with pharma partners. Innovation is at the heart of our industry, and I am particularly interested in exploring how creative partnering approaches can advance our clinical development, broaden our clinical development strategy to reach more patients faster, and expand patient access to our therapies. During the interview process, I was impressed with AppyMed's passionate employees and culture. dedicated to developing life-changing therapies to address underserved patient populations. To both survive and thrive, we must achieve operational efficiency and excellence. While I acknowledge the significant organizational changes AFIMED has undergone over the past year, I am committed to continuous improvement and a growth mindset to ensure we are consistently delivering meaningful value to our key stakeholders. Before I turn the call over to Andreas, I want to express my sincere thanks to him and the role he served as acting CEO over the past several quarters. Now over to you, Andreas.